Delix Therapeutics develops small‑molecule psychoplastogens that rapidly induce structural and functional neural changes in targeted brain areas. Its compounds are inspired by psychedelic compounds but are engineered to preserve efficacy while avoiding hallucinogenic properties and other safety liabilities. The company is advancing multiple candidates through preclinical and clinical development with the goal of bringing FDA‑approved, take‑home medicines to patients. Delix intends to use new funds to grow its drug development program, expand its pipeline and platform, hire additional team members, and pursue strategic opportunities in 2022. The company is led by CEO Mark Rus and is based in Boston, MA. Financially, Delix recently completed a convertible note financing and secured a strategic credit facility to support its programs alongside a prior $70M Series A in September 2021. Delix Therapeutics is a Boston-based preclinical neuroscience company developing non-hallucinatory, neuroplasticity-promoting therapeutics called psychoplastogens to treat mental illness and other brain disorders at scale. Its small-molecule compounds are designed to rapidly induce structural and functional neural changes in targeted brain regions while avoiding the hallucinogenic effects of first-generation psychedelics. Delix's discovery engine has produced nearly 1,000 novel compounds and identified several potential clinical development candidates. Its most advanced, orally bioavailable analogs—profiled in Nature and Cell—seek to preserve long-lasting beneficial neural rewiring without the safety liabilities and access barriers of classic psychedelics. The company raised $70M in a Series A to advance its non-hallucinatory, take-home candidates into clinical trials and to expand its team. DLX-1 and DLX-7, the first two development candidates, are undergoing pre-IND safety and toxicology studies to enable clinical trials in 2022.

Total raised

$110M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Jan 2022